Very Late Scaffold Thrombosis after Everolimus-Eluting Bioresorbable Scaffold Implantation in Patients with Unremarkable Interim Surveillance Angiography

摘要

Purpose: Everolimus-eluting bioresorbable scaffolds (BRS) demonstrated an increased risk of very late scaffold thrombosis (VLScT) in comparison with conventional drug-eluting stents. However, characterization of VLScT cases remains scant and the role of interim angiographic surveillance in identifying patients at risk of VLScT is unclear. We therefore set out to identify angiographic predictors of VLScT in our present case series.